Download Sample
Add to CartAnti-inflammatory Therapeutics Market
By Drug Class;
Anti-inflammatory Biologics, NSAIDs and OthersBy Treatment;
Arthritis and Multiple SclerosisBy Sales Channel;
Prescription and Over-the-CounterBy Application;
Respiratory Conditions, Auto-immune Diseases and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Anti-Inflammatory Therapeutics Market Overview
Anti-Inflammatory Therapeutics Market (USD Million)
Anti-Inflammatory Therapeutics Market was valued at USD 83,185.41 million in the year 2024. The size of this market is expected to increase to USD 119,968.17 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.4%.
Anti-inflammatory Therapeutics Market
*Market size in USD million
CAGR 5.4 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 5.4 % |
| Market Size (2024) | USD 83,185.41 Million |
| Market Size (2031) | USD 119,968.17 Million |
| Market Concentration | Medium |
| Report Pages | 387 |
Major Players
- AbbVie, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Sanofi
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Anti-inflammatory Therapeutics Market
Fragmented - Highly competitive market without dominant players
The Anti-Inflammatory Therapeutics Market is witnessing rapid advancement due to the growing incidence of chronic inflammatory conditions like arthritis and autoimmune disorders. Approximately 52% of chronic pain prescriptions now include anti-inflammatory medications, underscoring their essential role in managing long-term health conditions.
Biologics Driving Targeted Treatment
A notable trend is the expanding use of biologic anti-inflammatory therapies, making up about 41% of current treatment regimens. These therapies are increasingly favored for their targeted action and lower side effect profiles, helping patients experience improved therapeutic results and better overall management of inflammation.
Rising Appeal of Non-Steroidal Options
The preference for non-steroidal anti-inflammatory drugs (NSAIDs) has grown significantly, with usage increasing by 34%. Their effectiveness in controlling pain without immunosuppressive risks makes them a preferred choice, especially for long-term treatment strategies where safety is a top concern.
Collaborative R&D Fueling Market Expansion
Industry players are expanding their pipelines through strategic collaborations, contributing to around 47% of development activity in this space. These partnerships are vital in accelerating research, reducing time to market, and ensuring the continuous introduction of innovative therapies for inflammation management.
Anti-Inflammatory Therapeutics Market Recent Developments
-
In October 2023, Zydus Lifesciences initiated a Phase 2 trial to assess the safety and efficacy of its anti-inflammatory therapy, ZYIL1, for amyotrophic lateral sclerosis (ALS). Approved by India’s CDSCO, the study aimed to suppress NLRP3 inflammasome effects. Chairman Pankaj R. Patel highlighted Zydus’ commitment to addressing unmet needs in ALS treatment.
-
In July 2023, AbbVie, Inc. announced that the first patient was dosed in the phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy for HS.
Anti-Inflammatory Therapeutics Market Segment Analysis
In this report, the Anti-Inflammatory Therapeutics Market has been segmented by Drug Class, Treatment, Sales Channel, Application, and Geography
Anti-Inflammatory Therapeutics Market, Segmentation by Drug Class
The Anti-Inflammatory Therapeutics Market has been segmented by Drug Class into Anti-inflammatory Biologics, NSAIDs, and Others.
Anti-inflammatory Biologics
Anti-inflammatory biologics dominate the market with a share of approximately 60%, driven by their targeted action and effectiveness in treating chronic inflammatory conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These therapies, including TNF inhibitors and interleukin blockers, are preferred for their superior efficacy and reduced systemic side effects compared to traditional drugs.
NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) account for nearly 30% of the market due to their widespread use in treating acute pain, inflammation, and fever. They are often the first line of treatment for musculoskeletal disorders, offering affordable and accessible symptom relief. Despite concerns over gastrointestinal and cardiovascular risks, their demand remains strong, especially in low- and middle-income countries.
Others
The "Others" segment contributes about 10% and includes corticosteroids, COX-2 inhibitors, and emerging small molecule drugs. These therapies play important roles in cases where patients are non-responsive or intolerant to NSAIDs or biologics. Ongoing research is expanding this segment, particularly in the development of novel anti-inflammatory mechanisms.
Anti-Inflammatory Therapeutics Market, Segmentation by Treatment
The Anti-Inflammatory Therapeutics Market has been segmented by Treatment into Arthritis and Multiple Sclerosis.
Arthritis
Arthritis accounts for nearly 70% of the anti-inflammatory therapeutics market, driven by the high global prevalence of osteoarthritis and rheumatoid arthritis. Treatments often include NSAIDs, corticosteroids, and biologics, especially TNF inhibitors. The chronic nature of the disease fuels continuous demand for long-term inflammation control and pain management.
Multiple Sclerosis
Multiple sclerosis (MS) holds about 30% of the market, with growth supported by advances in immunomodulatory and biologic therapies. Anti-inflammatory treatments for MS aim to reduce neurological inflammation and delay disease progression. Rising awareness, improved diagnostic capabilities, and new drug approvals are contributing to the steady expansion of this segment.
Anti-Inflammatory Therapeutics Market, Segmentation by Sales Channel
The Anti-Inflammatory Therapeutics Market has been segmented by Sales Channel into Prescription and Over-the-Counter.
Prescription
Prescription-based anti-inflammatory therapeutics dominate the market with a share of around 75%, largely driven by the demand for biologics, immunosuppressants, and advanced therapies used in managing chronic inflammatory conditions. These drugs require clinical oversight due to potential side effects and targeted mechanisms of action. The rising prevalence of autoimmune diseases continues to boost prescription volumes.
Over-the-Counter
Over-the-counter (OTC) products hold approximately 25% of the market, fueled by widespread use of NSAIDs and topical analgesics for mild pain and inflammation relief. These drugs are favored for their easy accessibility and low cost, making them a go-to option for short-term symptom management. Expanding retail and e-commerce availability supports the steady growth of this segment.
Anti-Inflammatory Therapeutics Market, Segmentation by Application
The Anti-Inflammatory Therapeutics Market has been segmented by Application into Respiratory Conditions, Auto-immune Diseases, and Others.
Respiratory Conditions
Respiratory conditions account for approximately 30% of the anti-inflammatory therapeutics market, driven by the increasing prevalence of asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory airway disorders. Treatments often include corticosteroids and inhaled anti-inflammatory agents. The rising impact of air pollution and allergen exposure continues to boost demand in this segment.
Auto-immune Diseases
Auto-immune diseases dominate the application landscape, contributing about 55% to the market. Conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease are commonly treated with biologics and immunomodulators. The chronic nature of these illnesses ensures a consistent demand for long-term anti-inflammatory therapy.
Others
The "Others" segment makes up roughly 15% of the market and includes the treatment of dermatological conditions, post-surgical inflammation, and sports injuries. Products used in this category range from topical agents to oral NSAIDs. Growing consumer preference for self-medication in mild inflammation cases contributes to its gradual expansion.
Anti-Inflammatory Therapeutics Market, Segmentation by Geography
In this report, the Anti-Inflammatory Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Regions and Countries Analyzed in this Report
Anti-Inflammatory Therapeutics Market Share (%), by Geographical Region
North America
North America leads the anti-inflammatory therapeutics market with a share of around 38%, attributed to a high burden of chronic inflammatory diseases, strong healthcare infrastructure, and the early adoption of biologic therapies. The presence of major pharmaceutical players and high healthcare spending further support regional dominance.
Europe
Europe holds approximately 27% of the global market, driven by growing demand for advanced treatments for autoimmune disorders and respiratory conditions. Favorable regulatory frameworks and rising geriatric populations across countries like Germany, France, and the UK contribute significantly to sustained market growth.
Asia Pacific
Asia Pacific represents about 22% of the market and is witnessing robust growth due to increasing healthcare expenditure, rising prevalence of chronic illnesses, and improved drug accessibility. Countries such as China, India, and Japan are driving demand, particularly through generic drug manufacturing and expanding patient pools.
Middle East & Africa
The Middle East and Africa region accounts for nearly 7% of the market, supported by improving healthcare access, especially in urban centers. While the market is still emerging, the growing prevalence of asthma and autoimmune diseases, along with government initiatives to expand drug availability, are aiding its development.
Latin America
Latin America contributes around 6% to the global market, led by countries like Brazil, Mexico, and Argentina. Increasing awareness about inflammatory conditions, gradual improvements in healthcare infrastructure, and the availability of affordable anti-inflammatory medications are driving demand in this region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Anti-Inflammatory Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers:
- Aging Population
- Biologic Innovations
-
Rising Awareness - There has been a notable shift in societal attitudes towards health, with individuals becoming more proactive in managing their well-being. Patients are increasingly informed about the signs, symptoms, and consequences of inflammatory conditions, prompting them to seek timely medical intervention. Moreover, advancements in medical research and the dissemination of scientific knowledge through publications and conferences contribute to a deeper understanding of inflammatory diseases among healthcare providers and patients alike.
The advent of social media and online health communities has facilitated the sharing of personal experiences and treatment outcomes, fostering a sense of solidarity among individuals affected by inflammatory conditions. This digital interconnectedness has empowered patients to advocate for better access to treatment options and participate actively in shared decision-making with their healthcare providers.
Governmental and non-governmental organizations are playing an instrumental role in raising awareness about inflammatory diseases through public health campaigns, educational initiatives, and policy advocacy. These efforts aim to destigmatize inflammatory conditions, improve early detection rates, and promote adherence to treatment regimens.
Restraints:
- Side Effects
- Cost Constraints
-
Patent Expiry - For pharmaceutical companies, patent expirations translate into the loss of market exclusivity and a subsequent decline in revenue as cheaper generic alternatives flood the market. This erosion of market share can be particularly acute for blockbuster anti-inflammatory drugs, which often generate substantial profits. Generic competition drives down drug prices, impacting profitability and potentially leading to reduced investments in research and development for new therapies.
Patent expiry may result in a decrease in brand loyalty among patients and healthcare providers, as generic versions are often perceived as equally effective but more cost-effective alternatives. This can further erode sales of originator drugs, exacerbating the revenue decline for pharmaceutical companies.
The impact of patent expiry extends beyond individual companies to the broader anti-inflammatory therapeutics market. While generic competition can lower treatment costs and improve accessibility for patients, it also poses challenges in terms of maintaining innovation and investment in new drug development. The decreased revenue from originator drugs may deter companies from investing in research and development for novel anti-inflammatory therapies, potentially stifling innovation in the long term.
Opportunities:
- Emerging Markets
- Personalized Medicine
-
New Drug Approvals - One of the key areas of opportunity lies in addressing unmet medical needs, particularly in severe and refractory inflammatory conditions. New drug approvals enable the expansion of treatment options for patients who may not respond adequately to existing therapies or who experience intolerable side effects. Additionally, the approval of biosimilars—biologic drugs that are highly similar to existing biologics—offers cost-effective alternatives, increasing accessibility to life-changing treatments for a broader patient population.
Advancements in drug discovery and development technologies, such as high-throughput screening and computational modeling, facilitate the identification and optimization of novel anti-inflammatory compounds. This accelerates the pace of new drug approvals, shortening the timeline from preclinical research to clinical application. Regulatory agencies, recognizing the urgent need for innovative therapies, are implementing expedited review pathways and providing incentives for the development of orphan drugs targeting rare inflammatory conditions.
Strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are also driving new drug approvals. These partnerships leverage complementary expertise and resources, fostering innovation and accelerating the translation of scientific discoveries into clinically viable treatments. Moreover, increased investment in precision medicine approaches, including biomarker-driven drug development and patient stratification strategies, enhances the likelihood of successful new drug approvals by enabling more targeted and personalized therapeutic interventions.
Competitive Landscape Analysis
Key players in Global Anti-Inflammatory Therapeutics Market include:
- AbbVie, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Sanofi
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
-
Market Snapshot, By Treatment
-
Market Snapshot, By Sales Channel
- Market Snapshot, By Application
- Market Snapshot, By Region
- Anti-Inflammatory Therapeutics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Aging Population
-
Biologic Innovations
-
Rising Awareness
-
- Restraints
-
Side Effects
-
Cost Constraints
-
Patent Expiry
-
- Opportunities
-
Emerging Markets
-
Personalized Medicine
-
New Drug Approvals
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Anti-Inflammatory Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
-
Anti-inflammatory Biologics
-
NSAIDs
-
Others
-
- Anti-Inflammatory Therapeutics Market, By Treatment, 2021 - 2031 (USD Million)
- Arthritis
- Multiple Sclerosis
- Anti-Inflammatory Therapeutics Market, By Sales Channe, 2021 - 2031 (USD Million)
- Prescription
- Over-the-Counter
- Anti-Inflammatory Therapeutics Market, By Application, 2021 - 2031 (USD Million)
-
Respiratory Conditions
-
Auto-immune Diseases
-
Others
-
- Anti-Inflammatory Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Anti-Inflammatory Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AbbVie, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Sanofi
- Company Profiles
- Analyst Views
- Future Outlook of the Market